Australia markets closed

Restoration Robotics Inc. Regis (0RR.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.35600.0000 (0.00%)
As of 08:55PM CEST. Market open.
Full screen
Previous close0.3560
Open0.3320
Bid0.3480 x 0
Ask0.3740 x 0
Day's range0.3300 - 0.3680
52-week range0.3300 - 2.7200
Volume0
Avg. volume32
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Insiders who bought stock earlier this year lose -US$216k as Venus Concept Inc. (NASDAQ:VERO) drops to US$29m

    Insiders who bought US$360k worth of Venus Concept Inc.'s ( NASDAQ:VERO ) stock at an average buy price of US$1.12 over...

  • GlobeNewswire

    Venus Concept Announces First Quarter of Fiscal Year 2022 Financial Results; Reaffirms Fiscal Year 2022 Revenue Guidance

    TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2022. First Quarter 2022 Summary & Recent Highlights: Total revenue of $26.4 million, up $3.8 million, or 17%, year-over-year. U.S. revenue of $13.1 million, up $2.6 million, or 25%, year-over-year.Total subscription and system revenue of $22.3 million, up $4.0 million, or 22%

  • GlobeNewswire

    Venus Concept Receives New FDA 510(k) Clearance for Venus BlissMAX

    Clearance Expands Indications for Use to Include Non-Invasive Lipolysis of the Back and Thighs and Increases Maximum Energy Output to 150 WattsTORONTO, April 28, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market the Venus BlissMAX device (“BlissMAX”) with an expanded indication for use in ne